Safety analysis
Mild adhesion of the nasal cavity occurred in 3 patients in the control group, 3 patients in the rh-bFGF nasal-spray group and 2 patients in the rh-bFGF nasal-drop group. No significant difference in the adverse event rate was found among the three groups (P=0.86). No extensive adhesion and no major side effects were reported during the trial.